Cdc20 and securin overexpression predict short-term breast cancer survival

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2905-2913

  Karra, H ^a   Repo, H ^a   Ahonen, I ^b   Loyttyniemi E ^b   Pitkanen R ^c   Lintunen, M ^a   Kuopio, T ^c   Soderstrom M ^a   Kronqvist, P ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Cdc20; Prognosis; Securin

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; CDC20 PROTEINS; DNA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; SECURIN; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902543340     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.252     Document Type: Article

References (67)

1. Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22: 1233-1239
2. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306-311
3. Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA (2010) Triple-negative breast cancers: Unique clinical presentations and outcomes. Ann Surg Oncol 17(Suppl 3): 384-390
4. Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5: 15-8722-5-15
5. Chiorean R, Braicu C, Berindan-Neagoe I (2013) Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. Breast 22: 1026-1033
6. Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS (2006) Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 43: 1042-1052. (Pubitemid 43724628
7. Choi JW, Kim Y, Lee JH, Kim YS (2013) High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463: 681-687
8. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434. (Pubitemid 47219710
9. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-Term follow-up. Histopathology 19: 403-410
10. Fang G (2002) Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 13: 755-766
11. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948
12. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Panel members (2009) Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer (2009) Ann Oncol 20: 1319-1329
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747
14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795
15. Iacomino G, Medici MC, Napoli D, Russo GL (2006) Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line. J Cell Biochem 99: 1122-1131. (Pubitemid 44673969
16. Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: Cutting through the mystery. Nat Rev Cancer 1: 109-117. (Pubitemid 33741886
17. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C (2001) Securin is required for chromosomal stability in human cells. Cell 105: 445-457. (Pubitemid 32520851
18. Jensen S, Segal M, Clarke DJ, Reed SI (2001) A novel role of the budding yeast separin Esp1 in anaphase spindle elongation: Evidence that proper spindle association of Esp1 is regulated by Pds1. J Cell Biol 152: 27-40. (Pubitemid 32102434
19. Jiang J, Jedinak A, Sliva D (2011) Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the downregulation of CDC20 and uPA. Biochem Biophys Res Commun 415: 325-329
20. Jiang J, Thyagarajan-Sahu A, Krchnak V, Jedinak A, Sandusky GE, Sliva D (2012) NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS One 7: E34283
21. Kakar SS, Malik MT (2006) Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol 29: 387-395
22. Karra H, Pitkanen R, Nykanen M, Talvinen K, Kuopio T, Soderstrom M, Kronqvist P (2012) Securin predicts aneuploidy and survival in breast cancer. Histopathology 60: 586-596
23. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106: 423-430
24. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27: 1562-1571. (Pubitemid 351347882
25. Kim D, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, Franklyn JA, McCabe CJ (2005a) Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24: 4861-4866. (Pubitemid 41076304
26. Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ (2007) Securin induces genetic instability in colorectal cancer by inhibiting doublestranded DNA repair activity. Carcinogenesis 28: 749-759. (Pubitemid 46523373
27. Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS (2005b) Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11: 473-482. (Pubitemid 40116869
28. Kim S, Yu H (2011) Mutual regulation between the spindle checkpoint and APC/C. Semin Cell Dev Biol 22: 551-558
29. Kumada K, Nakamura T, Nagao K, Funabiki H, Nakagawa T, Yanagida M (1998) Cut1 is loaded onto the spindle by binding to Cut2 and promotes anaphase spindle movement upon Cut2 proteolysis. Curr Biol 8: 633-641. (Pubitemid 28257967
30. Lakhani SR. International Agency for Research on Cancer, World Health Organization (2012) WHO Classification of Tumours of the Breast. International Agency for Research on Cancer: Lyon
31. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767
32. Li M, Fang X, Wei Z, York JP, Zhang P (2009) Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol 185: 983-994
33. Li M, York JP, Zhang P (2007) Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos. Mol Cell Biol 27: 3481-3488. (Pubitemid 46685222
34. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28: 81-92
35. Mora-Santos M, Castilla C, Herrero-Ruiz J, Giraldez S, Limon-Mortes MC, Saez C, Japon MA, Tortolero M, Romero F (2013) A single mutation in Securin induces chromosomal instability and enhances cell invasion. Eur J Cancer 49: 500-510
36. Moura IM, Delgado ML, Silva PM, Lopes CA, do Amaral JB, Monteiro LS, Bousbaa H (2013) High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 43: 225-231
37. Musacchio A, Salmon ED (2007) The spindle-Assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8: 379-393. (Pubitemid 46643240
38. Nasmyth K (1999) Separating sister chromatids. Trends Biochem Sci 24: 98-104
39. Nasmyth K, Peters JM, Uhlmann F (2000) Splitting the chromosome: Cutting the ties that bind sister chromatids. Science 288: 1379-1385
40. Nilsson J (2011) Cdc20 control of cell fate during prolonged mitotic arrest: Do Cdc20 protein levels affect cell fate in response to antimitotic compounds?. Bioessays 33: 903-909
41. O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR (2013) Therapeutic targets in triple negative breast cancer. J Clin Pathol 66: 530-542
42. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119: 599-607. (Pubitemid 43955714
43. Panguluri SK, Yeakel C, Kakar SS (2008) PTTG: An important target gene for ovarian cancer therapy. J Ovarian Res 1: 6
44. Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012: 217185
45. Perou CM, Sorlie T, Eisen MB, van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
46. Peters JM (2006) The anaphase promoting complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell Biol 7: 644-656
47. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M (2008) Pituitary tumor-Transforming gene in endocrine and other neoplasms: A review and update. Endocr Relat Cancer 15: 721-743
48. Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M, Knecht R (2005) Pituitary tumor-Transforming gene (PTTG): A novel target for anti-Tumor therapy. Anticancer Res 25: 121-125. (Pubitemid 40470100
49. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van De Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874. (Pubitemid 32878711
50. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398. (Pubitemid 37071889
51. Stagg J, Allard B (2013) Immunotherapeutic approaches in triple-negative breast cancer: Latest research and clinical prospects. Ther Adv Med Oncol 5: 169-181
52. Sudakin V, Chan GK, Yen TJ (2001) Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 154: 925-936. (Pubitemid 34286173
53. Suijkerbuijk SJ, Kops GJ (2008) Preventing aneuploidy: The contribution of mitotic checkpoint proteins. Biochim Biophys Acta 1786: 24-31
54. Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P (2008) Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer 99: 335-340
55. Talvinen K, Karra H, Hurme S, Nykänen M, Nieminen A, Anttinen J, Kuopio T, Kronqvist P (2009) Securin promotes the identification of favourable outcome in invasive breast cancer. Br J Cancer 101: 1005-1010
56. Tang Z, Bharadwaj R, Li B, Yu H (2001) Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Dev Cell 1: 227-237. (Pubitemid 33653058
57. Taniguchi K, Momiyama N, Ueda M, Matsuyama R, Mori R, Fujii Y, Ichikawa Y, Endo I, Togo S, Shimada H (2008) Targeting of CDC20 via small interfering RNA causes enhancement of the cytotoxicity of chemoradiation. Anticancer Res 28: 1559-1563. (Pubitemid 351892929
58. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N (2006) The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 4: 130-137. (Pubitemid 44047367
59. Thirthagiri E, Robinson CM, Huntley S, Davies M, Yap LF, Prime SS, Paterson IC (2007) Spindle assembly checkpoint and centrosome abnormalities in oral cancer. Cancer Lett 258: 276-285. (Pubitemid 350101025
60. Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-Transforming gene: Physiology and implications for tumorigenesis. Endocr Rev 28: 165-186. (Pubitemid 46984833
61. Weinstein J (1997) Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1. J Biol Chem 272: 28501-28511
62. Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T, Baum LG (1994) A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol 14: 3350-3363. (Pubitemid 24132747
63. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van De Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43. (Pubitemid 46174133
64. Wu WJ, Hu KS, Wang DS, Zeng ZL, Zhang DS, Chen DL, Bai L, Xu RH (2013) CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med 11: 142
65. Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, Maitra A, Selaru FM (2012) Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 11: 2729-2738
66. Yu R, Lu W, Chen J, McCabe CJ, Melmed S (2003) Overexpressed pituitary tumor-Transforming gene causes aneuploidy in live human cells. Endocrinology 144: 4991-4998. (Pubitemid 37378414
67. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410. (Pubitemid 43166128.